CN102830228A - 定量分析循环肿瘤细胞的试剂及试剂盒 - Google Patents
定量分析循环肿瘤细胞的试剂及试剂盒 Download PDFInfo
- Publication number
- CN102830228A CN102830228A CN2011101612247A CN201110161224A CN102830228A CN 102830228 A CN102830228 A CN 102830228A CN 2011101612247 A CN2011101612247 A CN 2011101612247A CN 201110161224 A CN201110161224 A CN 201110161224A CN 102830228 A CN102830228 A CN 102830228A
- Authority
- CN
- China
- Prior art keywords
- probe
- circulating tumor
- cancer
- ctc
- tumor cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 title claims abstract description 110
- 239000003153 chemical reaction reagent Substances 0.000 title abstract description 11
- 238000004445 quantitative analysis Methods 0.000 title abstract 2
- 239000000523 sample Substances 0.000 claims abstract description 86
- 238000012360 testing method Methods 0.000 claims abstract description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 69
- 235000019152 folic acid Nutrition 0.000 claims description 36
- 239000011724 folic acid Substances 0.000 claims description 36
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 33
- 229960000304 folic acid Drugs 0.000 claims description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 206010006187 Breast cancer Diseases 0.000 claims description 23
- 208000026310 Breast neoplasm Diseases 0.000 claims description 23
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims description 22
- 102100024028 Progonadoliberin-1 Human genes 0.000 claims description 22
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims description 22
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims description 22
- 229920001184 polypeptide Polymers 0.000 claims description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- -1 polyoxyethylene Polymers 0.000 claims description 14
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 12
- 238000010168 coupling process Methods 0.000 claims description 11
- 230000008878 coupling Effects 0.000 claims description 10
- 238000005859 coupling reaction Methods 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- 108700012941 GNRH1 Proteins 0.000 claims description 7
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 7
- 239000007850 fluorescent dye Substances 0.000 claims description 7
- 238000001215 fluorescent labelling Methods 0.000 claims description 7
- 238000010494 dissociation reaction Methods 0.000 claims description 5
- 230000005593 dissociations Effects 0.000 claims description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 150000004985 diamines Chemical class 0.000 claims description 4
- 150000001413 amino acids Chemical group 0.000 claims description 3
- 239000013558 reference substance Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 238000001514 detection method Methods 0.000 abstract description 25
- 238000000684 flow cytometry Methods 0.000 abstract description 17
- 206010028980 Neoplasm Diseases 0.000 description 77
- 201000011510 cancer Diseases 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 55
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 26
- 201000005202 lung cancer Diseases 0.000 description 24
- 208000020816 lung neoplasm Diseases 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 206010060862 Prostate cancer Diseases 0.000 description 20
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 16
- 238000012113 quantitative test Methods 0.000 description 15
- 239000012103 Alexa Fluor 488 Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000002512 chemotherapy Methods 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 9
- 241000208340 Araliaceae Species 0.000 description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 description 8
- 235000008434 ginseng Nutrition 0.000 description 8
- 229940022353 herceptin Drugs 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 8
- 238000009792 diffusion process Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 6
- 239000012114 Alexa Fluor 647 Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000000432 density-gradient centrifugation Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229960000575 trastuzumab Drugs 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000005864 Sulphur Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 150000003457 sulfones Chemical class 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940064302 folacin Drugs 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 101710160107 Outer membrane protein A Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000005266 circulating tumour cell Anatomy 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000005477 standard model Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- HLUQDWRHBPWVNT-LVHVEONVSA-N (4s)-4-amino-5-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[(2s)-2-(carboxymethylcarbamoyl)pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropa Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 HLUQDWRHBPWVNT-LVHVEONVSA-N 0.000 description 1
- CCMKPCBRNXKTKV-UHFFFAOYSA-N 1-hydroxy-5-sulfanylidenepyrrolidin-2-one Chemical compound ON1C(=O)CCC1=S CCMKPCBRNXKTKV-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine group Chemical group N[C@H](CCCCN)C(=O)O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 208000009129 Ear Neoplasms Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102000008238 LHRH Receptors Human genes 0.000 description 1
- 108010021290 LHRH Receptors Proteins 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010035610 Pleural Neoplasms Diseases 0.000 description 1
- 206010068771 Soft tissue neoplasm Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 231100000768 Toxicity label Toxicity 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 201000003761 Vaginal carcinoma Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- GPWDPLKISXZVIE-UHFFFAOYSA-N cyclo[18]carbon Chemical compound C1#CC#CC#CC#CC#CC#CC#CC#CC#C1 GPWDPLKISXZVIE-UHFFFAOYSA-N 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000000349 mediastinal cancer Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000018280 neoplasm of mediastinum Diseases 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 206010061311 nervous system neoplasm Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 208000020717 oral cavity carcinoma Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 208000030940 penile carcinoma Diseases 0.000 description 1
- 201000008174 penis carcinoma Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 201000003437 pleural cancer Diseases 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110161224.7A CN102830228B (zh) | 2011-06-15 | 2011-06-15 | 定量分析循环肿瘤细胞的试剂及试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110161224.7A CN102830228B (zh) | 2011-06-15 | 2011-06-15 | 定量分析循环肿瘤细胞的试剂及试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102830228A true CN102830228A (zh) | 2012-12-19 |
CN102830228B CN102830228B (zh) | 2015-01-21 |
Family
ID=47333435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110161224.7A Active CN102830228B (zh) | 2011-06-15 | 2011-06-15 | 定量分析循环肿瘤细胞的试剂及试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102830228B (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103439509A (zh) * | 2013-09-06 | 2013-12-11 | 潘世扬 | 特异性循环非小细胞肺癌细胞标志物的应用 |
CN103923192A (zh) * | 2013-01-15 | 2014-07-16 | 国家纳米科学中心 | 用于富集、分离和检测循环肿瘤细胞的多肽及其应用 |
CN103940997A (zh) * | 2014-03-21 | 2014-07-23 | 上海柏慧康生物科技有限公司 | 一种乳腺癌循环肿瘤细胞检测系统及试剂盒 |
CN105158474A (zh) * | 2015-09-18 | 2015-12-16 | 安徽省立医院 | 一种用于检测血清her2的试剂盒及用途 |
CN108562569A (zh) * | 2018-06-04 | 2018-09-21 | 中国人民解放军第二军医大学 | 一种基于表面增强拉曼光谱探针的循环肿瘤细胞检测方法 |
CN108795869A (zh) * | 2018-06-28 | 2018-11-13 | 亚能生物技术(深圳)有限公司 | 一种循环肿瘤细胞阳性富集方法 |
TWI656344B (zh) * | 2016-01-06 | 2019-04-11 | 長庚大學 | Method for screening circulating tumor cells in blood |
WO2023066257A1 (zh) * | 2021-10-18 | 2023-04-27 | 珠海横琴爱姆斯坦生物科技有限公司 | 一种高灵敏度检测细胞群中极少量杂细胞的方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106319069B (zh) * | 2016-09-28 | 2020-02-14 | 河南乾坤科技有限公司 | 一种精确测定病源细胞的试剂盒及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006041959A2 (en) * | 2004-10-06 | 2006-04-20 | Wellstat Biologics Corporation | Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment |
WO2008140653A2 (en) * | 2007-03-14 | 2008-11-20 | Taligen Therapeutics, Inc. | Humaneered anti-factor b antibody |
WO2009092049A1 (en) * | 2008-01-17 | 2009-07-23 | Irm Llc | Improved anti-trkb antibodies |
CN101522716A (zh) * | 2006-10-02 | 2009-09-02 | 瑞泽恩制药公司 | 抗人il-4受体的高亲和力人抗体 |
-
2011
- 2011-06-15 CN CN201110161224.7A patent/CN102830228B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006041959A2 (en) * | 2004-10-06 | 2006-04-20 | Wellstat Biologics Corporation | Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment |
CN101522716A (zh) * | 2006-10-02 | 2009-09-02 | 瑞泽恩制药公司 | 抗人il-4受体的高亲和力人抗体 |
WO2008140653A2 (en) * | 2007-03-14 | 2008-11-20 | Taligen Therapeutics, Inc. | Humaneered anti-factor b antibody |
WO2009092049A1 (en) * | 2008-01-17 | 2009-07-23 | Irm Llc | Improved anti-trkb antibodies |
Non-Patent Citations (1)
Title |
---|
EKATERINA I. GALANZHA ET AL.: "In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells", 《NAT NANOTECHNOL》, vol. 4, no. 12, 15 November 2009 (2009-11-15), pages 855 - 860, XP002594057, DOI: doi:10.1038/NNANO.2009.333 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103923192A (zh) * | 2013-01-15 | 2014-07-16 | 国家纳米科学中心 | 用于富集、分离和检测循环肿瘤细胞的多肽及其应用 |
CN103923192B (zh) * | 2013-01-15 | 2016-03-16 | 北京中科纳泰生物科技有限公司 | 用于富集、分离和检测循环肿瘤细胞的多肽及其应用 |
CN103439509A (zh) * | 2013-09-06 | 2013-12-11 | 潘世扬 | 特异性循环非小细胞肺癌细胞标志物的应用 |
CN103940997A (zh) * | 2014-03-21 | 2014-07-23 | 上海柏慧康生物科技有限公司 | 一种乳腺癌循环肿瘤细胞检测系统及试剂盒 |
CN105158474A (zh) * | 2015-09-18 | 2015-12-16 | 安徽省立医院 | 一种用于检测血清her2的试剂盒及用途 |
TWI656344B (zh) * | 2016-01-06 | 2019-04-11 | 長庚大學 | Method for screening circulating tumor cells in blood |
CN108562569A (zh) * | 2018-06-04 | 2018-09-21 | 中国人民解放军第二军医大学 | 一种基于表面增强拉曼光谱探针的循环肿瘤细胞检测方法 |
CN108562569B (zh) * | 2018-06-04 | 2021-01-01 | 中国人民解放军第二军医大学 | 一种基于表面增强拉曼光谱探针的循环肿瘤细胞检测方法 |
CN108795869A (zh) * | 2018-06-28 | 2018-11-13 | 亚能生物技术(深圳)有限公司 | 一种循环肿瘤细胞阳性富集方法 |
WO2023066257A1 (zh) * | 2021-10-18 | 2023-04-27 | 珠海横琴爱姆斯坦生物科技有限公司 | 一种高灵敏度检测细胞群中极少量杂细胞的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102830228B (zh) | 2015-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102830228B (zh) | 定量分析循环肿瘤细胞的试剂及试剂盒 | |
Sörensen et al. | Measuring HER2-receptor expression in metastatic breast cancer using [68Ga] ABY-025 Affibody PET/CT | |
CN106796239B (zh) | 用于诊断胰腺癌的组合物以及使用其诊断胰腺癌的方法 | |
Yu et al. | Diagnostic potential of serum exosomal colorectal neoplasia differentially expressed long non-coding RNA (CRNDE-p) and microRNA-217 expression in colorectal carcinoma | |
CN104316683B (zh) | 针对全血的卵巢癌细胞检测试剂盒 | |
Yang et al. | Highly specific and sensitive point-of-care detection of rare circulating tumor cells in whole blood via a dual recognition strategy | |
Cheng et al. | Precise integrin-targeting near-infrared imaging-guided surgical method increases surgical qualification of peritoneal carcinomatosis from gastric cancer in mice | |
CN104568923A (zh) | 电化学发光检测外周血循环肿瘤细胞抗原的方法及试剂盒 | |
US20180250360A1 (en) | Method for detecting cancer cells, reagent for introducing substance into cancer cells, and composition for treating cancer | |
Okarvi et al. | Development of the tumor-specific antigen-derived synthetic peptides as potential candidates for targeting breast and other possible human carcinomas | |
CN112379096A (zh) | 一种外泌体膜蛋白作为结肠癌诊断标志物的应用以及结肠癌早期诊断试剂盒 | |
Yun et al. | A high-affinity repebody for molecular imaging of EGFR-expressing malignant tumors | |
CN101492505B (zh) | 一种肺癌特异性结合多肽及其制备方法和应用 | |
Guan et al. | Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo | |
CN102495215A (zh) | 一种定量检测肿瘤坏死因子α的试剂盒 | |
Balagurunathan et al. | Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer | |
Handula et al. | Towards complete tumor resection: Novel dual-modality probes for improved image-guided surgery of grpr-expressing prostate cancer | |
Cong et al. | A truncated DNA aptamer with high selectivity for estrogen receptor-positive breast cancer cells | |
Fujiwara et al. | 111 In-labeled anti-cadherin17 antibody D2101 has potential as a noninvasive imaging probe for diagnosing gastric cancer and lymph-node metastasis | |
CN106248971B (zh) | 用于检测人血清中her2含量的elisa试剂盒、使用方法及用途 | |
CN102520176A (zh) | 一种定量检测白介素8的试剂盒 | |
CN103675277B (zh) | 流式细胞术鉴别诊断横纹肌肉瘤与神经母细胞瘤骨髓转移及白血病的荧光探针及试剂盒 | |
Jiang et al. | Development and evaluation of a peptide heterodimeric tracer targeting CXCR4 and integrin αvβ3 for pancreatic cancer imaging | |
CN107271672B (zh) | 外泌体p-ERK在制备结直肠癌诊断产品中的应用 | |
Guan et al. | Sulfonamide derivative targeting carbonic anhydrase IX as a nuclear imaging probe for colorectal cancer detection in vivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 201203 Shanghai Zhangjiang High Tech Park of Pudong Cailun Road No. 5 building 103 room 399 Applicant after: GENOSABER BIOTECHNOLOGY (SHANGHAI) Co.,Ltd. Address before: 201203 Shanghai Zhangjiang High Tech Park of Pudong New Area Cailun Road No. 1 Building No. 311 room 720 Applicant before: MIAOHUA SIBO BIOLOG TECHNOLOGY SHANGHAI Co.,Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: MIAOHUA SIBO BIOLOGICAL TECHNOLOGY (SHANGHAI) CO., LTD. TO: GENOSABER BIOTECHNOLOGY (SHANGHAI) CO., LTD. |
|
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Herzejet Inventor after: He Wei Inventor after: Yang Guohua Inventor after: Lv Juan Inventor after: Han Ningning Inventor before: He Wei Inventor before: Yang Guohua Inventor before: Lv Juan Inventor before: Han Ningning |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: HE WEI YANG GUOHUA LV JUAN HAN NINGNING TO: HE JIE HE WEI YANG GUOHUA LV JUAN HAN NINGNING |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 201203 Shanghai Zhangjiang High Tech Park of Pudong Cailun Road No. 5 building 103 room 399 Patentee after: GENOSABER BIOTECH (SHANGHAI) Co.,Ltd. Address before: 201203 Shanghai Zhangjiang High Tech Park of Pudong Cailun Road No. 5 building 103 room 399 Patentee before: GENOSABER BIOTECHNOLOGY (SHANGHAI) Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230803 Address after: No. 26, Lane 908, Ziping Road, Zhoupu Town, Pudong New Area, Shanghai, 201318 Patentee after: GENOSABER BIOTECH (SHANGHAI) Co.,Ltd. Patentee after: Jiangsu Genuo Biotechnology Co.,Ltd. Address before: Room 103, Building 5, No. 399 Cailun Road, Zhangjiang High tech Park, Pudong, Shanghai, March 2012 Patentee before: GENOSABER BIOTECH (SHANGHAI) Co.,Ltd. |
|
TR01 | Transfer of patent right |